| Part A: Whole group | ||||
| Measurement | Whole group | No progression | Progression | p Value |
| (n = 89) | (n = 53) | (n = 36) | ||
| median (IQR) | median (IQR) | median (IQR) | ||
| Age (years) | 36.5 (29.6; 43.5) | 34.2 (29.4; 42.3) | 39.3 (33.2; 47.6) | ns |
| Sex (M/F) | 34/55 | 16/37 | 18/18 | ns* |
| Disease type (relapse-onset/progressive-onset) | 74/15 | 49/4 | 25/11 | 0.008* |
| Use of DMT (yes/no) | 21/68 | 14/39 | 7/29 | ns* |
| Disease duration (years) | 1.6 (0.7; 4.1) | 1.5 (0.6; 3.7) | 2.6 (0.8; 4.5) | ns |
| EDSS baseline | 2.0 (2.0; 3.0) | 2.5 (2.0; 3.0) | 2.0 (1.6; 3.0) | ns |
| EDSS follow-up | 2.5 (2.0; 3.5) | 2.0 (1.8; 3.0) | 3.5 (3.0; 5.4) | <0.001 |
| Progression rate (change EDSS/year) | 0.2 (0.0; 0.5) | 0.0 (−0.3; 0.3) | 0.7 (0.5; 1.0) | <0.001 |
| Part B: Relapse-onset group | ||||
| Measurement | Whole group | No progression | Progression | p Value |
| (n = 74) | (n = 49) | (n = 25) | ||
| median (IQR) | median (IQR) | median (IQR) | ||
| Age (years) | 35.5 (29.4; 42.6) | 34.2 (29.4; 42.8) | 35.8 (27.5; 42.6) | ns |
| Sex (M/F) | 23/51 | 14/35 | 9/16 | ns* |
| Use of DMT (yes/no) | 21/53 | 14/35 | 7/18 | ns* |
| Disease duration (years) | 1.7 (0.6; 4.4) | 1.5 (0.6; 3.8) | 3.7 (0.7; 4.8) | ns |
| EDSS baseline | 2.0 (1.9; 2.6) | 2.5 (2.0; 3.0) | 2.0 (1.5; 2.5) | 0.021 |
| EDSS follow-up | 2.5 (2.0; 3.0) | 2.0 (1.5; 3.0) | 3.0 (2.5; 4.0) | <0.001 |
| Progression rate (change EDSS/year) | 0.2 (0.0; 0.5) | 0.0 (−0.3; 0.2) | 0.7 (0.5; 1.0) | <0.001 |
Progression, increase in EDSS of at least 1 point ; p value, Mann–Whitney U test was used to test for differences between the progression and the no progression group
IQR, interquartile range (25%; 75%)
*Pearson chi-square
DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; F, female; M, male.